Ose Immunotherapeutics

Ose Immunotherapeutics est une entreprise française de biotechnologie dont le siège est à Nantes en France. Elle développe différents types d'immunothérapies.

Filings

96 filings

All Inside information96 Voting rights and capital15 Earnings release10 AGM documents8 Threshold crossing5 Share buyback4 Universal registration document3 Half-year financial report1

28/05/2026
OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
Inside informationFR
22/05/2026
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
Inside informationFR
27/04/2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
Inside informationFR
23/04/2026
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
Inside informationFR
15/04/2026
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
Inside informationFR
14/04/2026
OSE Immunotherapeutics Evolves its Leadership Team
Inside informationFR
16/03/2026
OSE Immunotherapeutics Announces its 2026 Financial Calendar
Inside informationFR
10/03/2026
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
Inside informationFR
02/03/2026
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®
Inside informationFR
26/02/2026
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
Inside informationFR
29/01/2026
OSE Immunotherapeutics sélectionne la pouchite chronique et l’hidradénite suppurée comme nouvelles indications clés pour Lusvertikimab
Inside informationFrench
21/01/2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
Inside informationFR
20/01/2026
Half-Year Report on Liquidity Contract with Invest Securities
Inside information
09/12/2025
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
Inside informationFR
08/12/2025
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
Inside informationFR
17/11/2025
OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
Inside informationFR
07/11/2025
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
Inside informationFR
03/10/2025
Appointment of Marc Le Bozec as Interim CEO
Inside informationFR
30/09/2025
Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
Inside informationFR
26/09/2025
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
Inside informationFR
25/09/2025
OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025
Inside informationFR
24/09/2025
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
Inside informationFR
23/09/2025
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
Inside informationFR
22/09/2025
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
Inside informationFR
12/09/2025
Mise à jour de l’information relative à l’Assemblée Générale du 30 septembre 2025-Constitution d’un pacte réunissant 61 actionnaires fondateurs, historiques, salariés et dirigeants de la Société portant sur environ 20,1% des droits de vote
Inside informationFrench
11/09/2025
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer
Inside informationFR
08/09/2025
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025
Inside informationFR
04/09/2025
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
Inside information
29/08/2025
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
Inside informationFR
25/08/2025
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
Inside informationFR
20/08/2025
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
Inside informationFR
17/07/2025
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
Inside informationFR
02/07/2025
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
Inside informationFR
30/06/2025
OSE Immunotherapeutics Publishes Letter to Shareholders
Inside informationFR
25/06/2025
OSE Immunotherapeutics provides an update on ongoing proceedings
Inside informationFR
20/06/2025
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
Inside informationFR
11/06/2025
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
Inside informationFR
04/06/2025
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
Inside informationFR
02/06/2025
OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer
Inside informationFR
23/05/2025
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPa Blockade in Two Ongoing Trials at ASCO 2025
Inside informationFR
21/05/2025
OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies
Inside informationFR
05/05/2025
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
Inside informationFR

About

ISIN: FR0012127173
Ticker: OSE
LEI: 969500HIUWVGY6NZSM05
Sector: Health care
Founded: 2016
Country of registration: FR
Last filing: 08/07/2026, 18:00

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive